Brain tumor therapy needs longer trea...( ll -- before coming to rest destroying...),Health

Although BNCT has been moderately successful at treating tumors in clinical trials, the invading cell clusters have proved resistant to treatment, taking up less BPA than their counterparts in the main tumor mass. The new research indicates that with a longer drug infusion time, the BPA levels in the invading cells could come closer to those in the main tumor mass.

Other authors of the Cancer Research paper are Rolf F. Barth and Weilian Yang, Department of Pathology, Ohio State University; and Darrel D. Joel and Jeffrey A. Coderre, Brookhaven National Laboratory. Coauthors of the Clinical Cancer Research paper are George W. Kabalka, Department of Chemistry, University of Tennessee; and Jeffrey A. Coderre, Department of Nuclear Engineering, Massachusetts Institute of Technology.

All three research projects were supported by the U.S. Department of Energy, which recently awarded the Cornell laboratory a three-year, $829,000 grant to continue the cancer research using ion microscopy.

This article was prepared by Cornell News Service science intern Lissa Harris

'"/>

Contact: David Brand
deb27@cornell.edu
607-255-3651
Cornell University News Service
1-Aug-2002